Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Supernus Pharmaceuticals (SUPN) Long-Term Deferred Tax (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Long-Term Deferred Tax for 6 consecutive years, with $38.4 million as the latest value for Q4 2025.

On a quarterly basis, Long-Term Deferred Tax changed N/A to $38.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $38.4 million, a N/A change, with the full-year FY2025 number at $38.4 million, changed N/A from a year prior.
Long-Term Deferred Tax was $38.4 million for Q4 2025 at Supernus Pharmaceuticals, up from $8.8 million in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $38.4 million in Q4 2025 to a low of $6.2 million in Q2 2025.